Your browser doesn't support javascript.
loading
Residual Disease Activity in Canadian Patients With Psoriatic Arthritis Treated With Advanced Therapies: Results From a Multiregistry Analysis (UNISON-PsA).
Gladman, Dafna D; Chandran, Vinod; Rosen, Cheryl F; Rohekar, Sherry; Boyd, Tristan; Eder, Lihi; Rahman, Proton; Dutz, Jan; Chan, Jonathan; Haydey, Richard P; Barac, Snezana; Laliberté, Marie-Claude; Girard, Tanya; Fournier, Pierre-André; Sutton, Mitchell; Pereira, Daniel; Chim, Tina; Coupal, Louis; Choquette, Denis.
Afiliación
  • Gladman DD; D.D. Gladman, MD, University of Toronto, Department of Medicine, Division of Rheumatology, and Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario; dafna.gladman@utoronto.ca.
  • Chandran V; V. Chandran, MBBS, MD, DM, PhD, University of Toronto, Department of Medicine, Division of Rheumatology, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario.
  • Rosen CF; C.F. Rosen, MD, Division of Dermatology, Department of Medicine, University of Toronto, and Division of Dermatology, Toronto Western Hospital, Toronto, Ontario.
  • Rohekar S; S. Rohekar, MD, Division of Rheumatology, Western University, London, Ontario.
  • Boyd T; T. Boyd, MD, Division of Rheumatology, Western University, and Division of Rheumatology, St. Joseph's Hospital, London, Ontario.
  • Eder L; L. Eder, MD, PhD, Division of Rheumatology, Women's College Hospital, and Department of Medicine, University of Toronto, Toronto, Ontario.
  • Rahman P; P. Rahman, MD, Department of Medicine, Memorial University, St. John's, Newfoundland.
  • Dutz J; J. Dutz, MD, Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia.
  • Chan J; J. Chan, MD, Department of Medicine, Division of Rheumatology, University of British Columbia, and Arthritis Research Canada, Vancouver, British Columbia.
  • Haydey RP; R.P. Haydey, MD, S. Barac, MD, Winnipeg Clinic, Winnipeg, Manitoba.
  • Barac S; R.P. Haydey, MD, S. Barac, MD, Winnipeg Clinic, Winnipeg, Manitoba.
  • Laliberté MC; M.C. Laliberté, PhD, T. Girard, PhD, P.A. Fournier, MSc, MBA, AbbVie Corp., St. Laurent, Quebec.
  • Girard T; M.C. Laliberté, PhD, T. Girard, PhD, P.A. Fournier, MSc, MBA, AbbVie Corp., St. Laurent, Quebec.
  • Fournier PA; M.C. Laliberté, PhD, T. Girard, PhD, P.A. Fournier, MSc, MBA, AbbVie Corp., St. Laurent, Quebec.
  • Sutton M; M. Sutton, MSc, D. Pereira, BSc, T. Chim, MSc, Center for Prognosis Studies in the Rheumatic Diseases, Psoriatic Disease Program, Toronto Western Hospital, University Health Network, Toronto, Ontario.
  • Pereira D; M. Sutton, MSc, D. Pereira, BSc, T. Chim, MSc, Center for Prognosis Studies in the Rheumatic Diseases, Psoriatic Disease Program, Toronto Western Hospital, University Health Network, Toronto, Ontario.
  • Chim T; M. Sutton, MSc, D. Pereira, BSc, T. Chim, MSc, Center for Prognosis Studies in the Rheumatic Diseases, Psoriatic Disease Program, Toronto Western Hospital, University Health Network, Toronto, Ontario.
  • Coupal L; L. Coupal, MSc, D. Choquette, MD, Institut de Rhumatologie de Montréal, CHUM, University of Montreal, Montreal, Quebec, Canada.
  • Choquette D; L. Coupal, MSc, D. Choquette, MD, Institut de Rhumatologie de Montréal, CHUM, University of Montreal, Montreal, Quebec, Canada.
J Rheumatol ; 51(5): 479-487, 2024 May 01.
Article en En | MEDLINE | ID: mdl-38359937
ABSTRACT

OBJECTIVE:

Although patient outcomes in psoriatic arthritis (PsA) have improved with the advent of advanced therapies, there remains a high unmet need to treat residual disease activity. The objective of the current study was to quantify residual disease activity and burden of disease in Canadian patients with PsA.

METHODS:

This was a multiregion, observational, retrospective analysis of patient data extracted from the Rhumadata and the International Psoriasis and Arthritis Research Team (IPART) registries, analyzing deidentified data from patients who had initiated advanced therapy for the treatment of PsA between January 2010 and December 2019. The primary endpoint was the proportion of patients failing to achieve minimal disease activity (MDA) within 6 months; secondary endpoints included clinical and patient-reported burden of disease. Descriptive statistics included summaries by region, treatment class, and number of prior advanced therapies.

RESULTS:

One thousand five hundred ninety-six patients were included. The proportions of patients who failed to achieve MDA within 6 months of an advanced therapy were 64.8% in Ontario, 68.3% in Western Canada, 74.8% in Quebec, and 75% in the Atlantic/East region. Failure to achieve MDA was higher among patients receiving an IL-17i compared with a TNFi in all regions except the Atlantic/East. Between 73.2% and 78.6% of patients reported pain at 6 months, and continuing functional impairment varied from 24% in the West to 83.3% in the Atlantic/East.

CONCLUSION:

There is substantial burden and unmet need for improved therapies for Canadians with PsA. There is a wide regional variation in outcomes that requires further assessment.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Índice de Severidad de la Enfermedad / Artritis Psoriásica / Sistema de Registros / Antirreumáticos Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: J Rheumatol Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Índice de Severidad de la Enfermedad / Artritis Psoriásica / Sistema de Registros / Antirreumáticos Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: J Rheumatol Año: 2024 Tipo del documento: Article